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Abstract
Background—An estimated 3600 infants born with congenital cytomegalovirus (cCMV) 
infection annually in the United States are symptomatic at birth. The proportion of infants with 
symptomatic cCMV infection who require hospitalization is unknown yet important for 
understanding the full disease and economic burdens of cCMV.
Methods—Data from the Healthcare Cost and Utilization Project Kids' Inpatient Databases were 
analyzed to determine numbers and rates of cCMV-related hospitalizations among infants for 
1997, 2000, 2003, 2006 and 2009, the years the survey was conducted. A cCMV-related 
hospitalization was defined as a hospitalization with an International Classification of Diseases, 
9th revision, Clinical Modification code of 771.1 in an infant without HIV or transplant-related 
codes. After applying hospital type-specific cost-to-charge ratios and adjusting to 2012 US dollars, 
total medical costs associated with cCMV-related hospitalizations were assessed. Results were 
extrapolated to represent national estimates.
Results—Among infants <1 year of age in the United States, an estimated annual average of 747 
cCMV-related hospitalizations (18.6/100,000 per year) were coded during the 5 study years; 408 
(55%) were among infants <1 month of age (122.0/100,000 per year). Approximately 4% of 
hospitalizations among infants <1 year resulted in death. Total estimated annual cost associated 
with cCMV-related hospitalizations among the US infants <1 year was at least $14.3 million.
Conclusions—cCMV infection is associated with substantial numbers of hospitalizations, 
medical costs and mortality among the US infants. The true burden and costs of cCMV disease are 
likely much higher than our estimates when underascertainment of cCMV and total costs related to 
services and hospitalizations beyond the first year of life are considered.
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Approximately 28,000 infants are believed to be infected with congenital cytomegalovirus 
(cCMV) annually in the United States.1,2 An estimated 12.7% of these infants, about 3600 
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children annually, are symptomatic at birth, 40% or ∼1400 of these children are estimated to 
develop permanent sequelae and 4% or ∼140 to die as a result of infection.3–6 The spectrum 
of severity or the level of medical care that children with symptomatic cCMV infection 
require is not well described.7 We used data from a nationally representative sample of 
pediatric hospital discharges for the United States to estimate the numbers and rates of 
symptomatic cCMV-related hospitalizations among infants <1 year of age, describe the 
characteristics of infants hospitalized with symptomatic cCMV and estimate the medical 
costs associated with symptomatic cCMV-related hospitalizations.
Materials and Methods
Data Source
Hospital discharge records were extracted from the Kids' Inpatient Databases (KID) for 
1997, 2000, 2003, 2006 and 2009. The KID are produced by the Healthcare Cost and 
Utilization Project (HCUP) within the Agency for Healthcare Research and Quality in 
collaboration with public and private statewide data organizations.8 The sampling frame for 
the KID includes a sample of pediatric discharges from all the US short-term, non-federal, 
general and other specialty hospitals recorded in state databases for 22, 27, 26, 38 and 44 
participating states for 1997, 2000, 2003, 2006 and 2009, respectively. Systematic random 
sampling was conducted to select 10% of uncomplicated in-hospital births and 80% of 
complicated in-hospital births and other pediatric discharges for children ≤18 years in 1997 
and ≤20 years in 2000, 2003, 2006 and 2009. The KID contain 2–3 million pediatric 
inpatient records from 2500 to 3500 hospitals per year.
Data Analysis
We defined a symptomatic cCMV-related hospitalization using the International 
Classification of Diseases, 9th revision, Clinical Modification (ICD-9-CM) codes as a 
hospitalization in an infant <1 year of age with a code for cCMV infection (771.1). We 
excluded those with codes for HIV (042) or transplant-related diagnoses [transplant (V42), 
transplant complication (996.8), transplant operation (E87.80)]. We examined symptomatic 
cCMV-related hospitalizations by sex, race/ethnicity, region of hospitalization based on 
standard census regions (Northeast, Midwest, South, West), hospital type (rural, urban 
teaching, urban nonteaching), hospital size (categorized by bed size as small, medium, large) 
and expected primary payer for hospitalization (Medicare, private insurance including health 
maintenance organizations, self-pay or other). We also examined symptomatic cCMV-
related hospitalization by age group (<1, 1–3, 4–7 and 8–11 months) for those 
hospitalizations with age data available in months, over the 5 study years.
Symptomatic cCMV-related conditions were defined using International Classification of 
Diseases, 9th revision, codes as follows: microcephaly (742.1), hepatomegaly (789.1, 
573.1), splenomegaly (789.2), thrombocytopenia (776.1, 287.3, 287.4, 287.5, 776.2), 
seizures (345, 779.0, 780.39), encephalitis (323, 058), other neurological symptoms (742), 
cerebral palsy (343), petechiae (772.6, 782.7), hearing loss (389, 315.34, 388.2) and 
chorioretinitis (363.0, 363.1, 363.2, 363.3). The presence of other conditions not specific to 
cCMV but that may occur in children with symptomatic cCMV, including low birth weight 
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[V213, 764, 765 (excludes 765.29)], jaundice [774 (excludes 774.0)], respiratory distress 
[769, 786, 770 (excludes 770.9), 799.1, 484.1, 518.81, 518.82, 518.83, 518.84, 519, 997.3], 
reflux (530.81, 530.11), hydrocephalus (331.4, 742.3) and failure to thrive (783.41), was 
also examined. Procedures potentially performed as the result of cCMV-related conditions 
were also examined, including mechanical ventilation (939.0, 939.1, 960.4, 967.0, 967.1, 
967.2), feeding tubes (431.1, 431.2, 431.3, 431.4, 431.5, 431.6, 431.7, 431.8, 431.9, 449.9) 
and transfusions (990). In addition, procedures including cochlear implants, 
ventriculoperitoneal shunts, hip reductions and fundoplications were examined but not 
presented because of small numbers.
The average annual number of days hospitalized was calculated by using the mean length of 
stay and multiplying by the average number of hospitalizations by year. Total medical costs 
for symptomatic cCMV-related hospitalizations were estimated among infants <1 year of 
age overall and by categories of age (<1, 1–3, 4–7 and 8–11 months), by converting total 
charges to costs using hospital-specific cost-to-charge ratios and adjusting for inflation to 
2012 US dollars. Hospital-specific cost-to-charge ratios were not available for data from 
years 1997 and 2000; thus, the cost-to-charge ratios from 2009 differentiated by hospital size 
and type were applied to 1997 and 2000 to convert charges to medical costs. In addition, 
weights were adjusted according to HCUP methodology9 to account for hospitalizations 
with missing charges data. More conservative estimates of rates and costs of symptomatic 
cCMV-related hospitalizations were also calculated by excluding hospitalizations with a 
code only for respiratory distress (no other cCMV-related conditions present), since 
respiratory distress alone is not a typical presentation of symptomatic cCMV.
Because individual identifiers are not available in the KID, the hospital discharge record was 
used as the unit of analysis and the numbers of discharges, rather than numbers of infants, 
with symptomatic cCMV-related hospitalizations were analyzed. The symptomatic cCMV-
related hospitalization numbers, rates and associated costs that we present are extrapolations 
from hospitalizations without missing age information to represent national estimates. 
Specifically, national estimates for the number of symptomatic cCMV-related 
hospitalizations, length of stay and total medical costs associated with hospitalization were 
calculated using the discharge weights developed for the HCUP.8 Estimates with a relative 
standard error >0.30 are considered statistically unreliable and are thus not presented.10
Rates of symptomatic cCMV-related hospitalizations were calculated as the estimated 
number of hospitalizations per 100,000 infants <1 year and <1 month of age using data from 
the US Census as the denominator. The denominator for infants <1 month of age was 
calculated by dividing the population for infants <1 year of age by 12, while the numerator 
included only estimated numbers for hospitalizations among infants with known age in 
months. Denominators obtained from vital records data were considered free from sampling 
error. Standard errors (SEs) and 95% confidence intervals (CIs) were calculated using 
SUDAAN release 10.0.1 (SAS Institute Inc., Cary, NC) to account for the complex survey 
design of the KID. Poisson regression was used to estimate statistical differences in 
incidence over the 5 study years and among major US geographical regions.
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Results
Symptomatic cCMV-related Hospitalization Rates and Characteristics
During the 5 study years, an estimated total of 3734 symptomatic cCMV-related 
hospitalizations occurred among infants <1 year of age in the United States. Of the total 
hospitalizations, 2755 (73.8%) had age data available in months; the median age of 
symptomatic cCMV-related hospitalizations was 0 months (mean: 1 month, range: 0–11 
months).
The estimated average number of annual symptomatic cCMV-related hospitalizations for all 
infants <1 year of age in the United States was 747 (range 677–823) with an overall annual 
estimated rate of 18.6 (95% CI: 18.5–18.7) per 100,000. Trends in symptomatic cCMV-
related hospitalization rates did not differ significantly over the study period or across the 
US regions (Table 1). Non-Hispanic whites represented the greatest proportion of 
symptomatic cCMV-related hospitalizations (35.1%) but non-Hispanic blacks had the 
highest rate (23.5/100,000; P = 0.001) (Table 1). The majority of symptomatic cCMV-
related hospitalizations occurred in hospitals classified as large (60.6%) and as urban 
teaching (72.3%) (Table 1). More than half of hospitalizations were covered by Medicaid 
(59.0%) and private insurance or health maintenance organizations were responsible for 
payment of 32.5% of hospitalizations.
Of symptomatic cCMV-related hospitalizations in the United States among infants <1 year, 
2042 (74.1%) were among infants <1 month, 403 (14.6%) among infants 1–3 months, 167 
(6.1%) among infants 4–7 months and 143 (5.2%) among infants 8–11 months of age (Table 
2). The estimated average number of annual symptomatic cCMV-related hospitalizations for 
infants <1 month of age was 408 (range 350–459) with an overall annual estimated rate of 
122.0 (95% CI: 121.9–122.1) per 100,000. Among the symptomatic cCMV-related 
hospitalizations in infants <1 month of age, up to 60% had a code for at least 1 cCMV-
related condition, with thrombocytopenia (48.3%) occurring most frequently. Low birth 
weight and respiratory distress were also common (58.0% and 52.6%, respectively); 36.4% 
of hospitalizations had codes for mechanical ventilation and 23.1% for transfusions (Table 
2). The most commonly coded cCMV-related conditions among older infant hospitalizations 
were thrombocytopenia (19.6%) among infants 1–3 months of age and seizures among 
infants 8–11 months of age (30.8%). Respiratory distress was common among symptomatic 
cCMV-related hospitalizations in infants 1–7 months of age; the proportion of symptomatic 
cCMV-related hospitalizations with a code for pneumonia increased from 5.4% in <1-month 
olds to 15.7% in 8–11-month olds. The proportion of symptomatic cCMV-related 
hospitalizations with codes related to mechanical ventilation decreased from 36.4% among 
infants <1 month of age to 17.4% in infants 1–3 months of age.
An estimated 157 (4.2%) symptomatic cCMV-related hospitalizations among infants <1 year 
ended in death; 88 (90.7%) were among infants <1 month of age. Among the estimated 157 
deaths among infants <1 year, 63.0% were male and 36.8% were non-Hispanic white; 42% 
occurred in infants with birth weight <1500 g. Thrombocytopenia was the most common 
cCMV-related code among the hospitalizations that ended in death (59.0%); respiratory 
distress was coded for in 85.2% and 30.2% had a neurologic code (ie, seizures, 
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microcephaly, other neurological symptoms). Of the 111 (69.8%) deaths that did not have a 
neurologic code, 84.9% had a code for respiratory distress, 67.9% for low birth weight and 
68.5% for thrombocytopenia.
Length of Stay and Cost of Symptomatic cCMV-related Hospitalizations
Overall, an estimated total number of 108,299 days (26,660 days annually) were associated 
with symptomatic cCMV-related hospitalizations during the 5 study years among infants <1 
year of age; 86.8% of the days hospitalized were accounted for by hospitalizations among 
infants <1 month of age, of which 54.4% were among infants <1 month who were <1500 g. 
The median length of hospitalization was 12.9 days (quartile range: 5–37 days) among 
infants <1 year, 15.5 days (quartile range: 6–45 days) among infants <1 month and 4.9 days 
(quartile range: 2–12 days) among infants 1–11 months of age. The median costs for 
hospitalization among infants <1 year, <1 month and 1–11 months of age were $19,100, 
$25,500 and $7600, respectively (Table, Supplemental Digital Content 1, http://
links.lww.com/INF/B927). Among infants <1 month, median length of hospitalization and 
cost were higher among those <1500 g compared with infants ≥1500 g (67.4 days and 
$102,300 versus 11.1 days and $17,600). Of the total annual costs of $14.3 million for 
symptomatic cCMV-related hospitalizations among infants <1 year of age, $10.4 million 
(72.7%) was accounted for by hospitalizations among infants <1 month of age, of which 
$10.1 million (97.6%) was accounted for by hospitalizations in infants <1 month with birth 
weight <1500 g. The total annual cost for symptomatic cCMV-related hospitalizations that 
ended in death was $1.7 million.
Excluding hospitalizations with codes only for respiratory distress resulted in more 
conservative estimates of symptomatic cCMV-related hospitalizations and costs of 3030 
total hospitalizations among children <1 year of age or 606 hospitalizations annually 
(15.1/100,000) for an estimated annual cost of $10 million.
Discussion
Using nationally representative hospital discharge data, we estimate that at least 747 
symptomatic cCMV-related hospitalizations resulting in ∼21,700 hospitalization days occur 
each year among infants <1 year, with just over half (55%) of the hospitalizations occurring 
among infants <1 month of age. An estimated 4% of the symptomatic cCMV-related 
hospitalizations ended in death. Costs were the highest for hospitalizations among infants <1 
month and those with birth weight <1500 g, which accounted for the bulk of the 
symptomatic cCMV hospitalization costs in the first year of life. Considering 
hospitalizations in the first year of life alone, symptomatic cCMV is associated with sizable 
morbidity, mortality and substantial medical costs, estimated to range from at least $10 to 
$14.3 million annually. The true costs of symptomatic cCMV disease among infants and 
young children are likely much higher than our estimates when costs related to services 
associated with feeding tubes, mechanical ventilation, specialized equipment, cochlear 
implants, re-evaluations, special education, hearing aids and hospitalizations beyond the first 
year of life are considered.7
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Data from a systematic review of population-based studies estimated that 12.7% of cCMV-
infected infants are symptomatic at birth,3 which would translate to approximately 3600 
symptomatic infants born annually in the United States. The proportion of these infants with 
disease severe enough to require hospitalization is not known. Dividing the average annual 
estimated number of symptomatic cCMV-related hospitalizations identified in our study for 
infants <1 month (408) by the estimated expected number of children born with 
symptomatic cCMV (3600) suggests that only ∼11% of the expected total number of infants 
with symptomatic cCMV infections had a cCMV-coded hospitalization. While symptomatic 
cCMV disease may not be severe enough to warrant hospitalization in all cases, it is likely 
that some proportion of infants with symptomatic cCMV infection goes undiagnosed or is 
not coded for and thus their conditions are not attributable to cCMV.
About 40% of the hospitalizations among infants <1 year with a cCMV code did not have 
codes for any cCMV-related conditions, raising the question of whether these 
hospitalizations were related to symptomatic cCMV infection. Signs and symptoms 
classically associated with cCMV, even when present, may not be comprehensively coded 
for in administrative data. As such, it is likely that we underascertained the number of 
cCMV-related conditions among those with a symptomatic cCMV-related hospitalization. It 
is possible that some of the hospitalizations we defined as cCMV-related may have occurred 
in infants whose hospitalizations were due to other conditions in whom asymptomatic 
cCMV infection was detected. However, it seems unlikely that there would have been many 
hospitalizations in which cCMV infections that did not contribute to the need for 
hospitalization would have been coded for in discharge data. We identified codes for 
respiratory distress in about 50% of the symptomatic cCMV-related hospitalizations among 
infants <1 year and <1 month. Although respiratory distress alone is not typically recognized 
as symptomatic cCMV, respiratory distress and lung disease have been described previously 
in infants with congenital infection.11 The extent to which respiratory distress was directly 
the result of cCMV infection or a result of prematurity, to which cCMV infection may have 
contributed, is unclear.
Information on symptomatic cCMV-related hospitalizations in the United States is limited 
and comes from data collected before 1990.12 Consistent with a study of symptomatic 
newborns with cCMV conducted in Alabama,12 we found that the median duration of 
hospitalization was longer among low birth weight compared with full-term infants. 
Compared with admission rates for cCMV-related hospitalizations among infants <1 month 
of age in Australia (443/100,000),13 the overall rate for symptomatic cCMV-related 
hospitalizations in infants <1 month of age in our study was almost 4 times lower 
(122/100,000). At least 2 reasons may explain such differences: (1) we excluded 
hospitalizations with HIV or transplant-related codes and (2) ascertainment of symptomatic 
cCMV infection may have been more complete in the Australian study. Without medical 
record validation and laboratory testing, we do not know the extent to which all infants with 
symptomatic cCMV are diagnosed. To better understand the true hospitalization burden in 
infancy that results from symptomatic cCMV infection, the proportion of infants with 
cCMV disease that is severe enough to require hospitalization and the extent to which 
cCMV disease is currently ascertained require additional study.
Lopez et al. Page 6
Pediatr Infect Dis J. Author manuscript; available in PMC 2017 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Published estimates of cCMV-related mortality among symptomatic children range from 4% 
to 30%.2,12,14,15 The annual number of deaths among infants <1 month and <1 year of age 
in the United States due to cCMV were estimated in our study to be 18 and 31, respectively. 
Extrapolating data from a population-based study of cCMV mortality in the United States by 
taking the total number of deaths for each age group in that study and dividing by the 17-
year study period16 yields similar numbers of deaths, 19 and 33 among infants <1 month and 
<1 year of age, respectively. In our study, the majority (70%) of hospitalizations among 
infants <1 year of age ending in death had codes for respiratory distress, low birth weight 
and/or thrombocytopenia. In contrast to a longitudinal study of children with symptomatic 
cCMV infection during infancy in which all infants who died had severe neurologic 
damage,14 only slightly less than a third of the deaths in our study were associated with a 
code for a neurologic condition (30%). The explanation for these differences is unclear as it 
seems likely that severe neurologic conditions, had they been present, would have been 
captured in hospitalization data. Hospitalization data may provide relatively complete 
estimates of the number of recognized cCMV-related deaths, as most deaths likely occur in 
hospitals, but they are likely not complete in listing all of the cCMV-related complications 
that may have led to the death. Additional studies are needed to better understand the extent 
to which additional cCMV-related deaths are occurring among hospitalized infants but go 
undiagnosed.
Our study was subject to limitations. By using hospital discharge data we were limited to 
estimating numbers of symptomatic cCMV-related hospitalizations in which cCMV 
infection was diagnosed and coded. The extent to which this overestimates the number of 
infants with symptomatic cCMV who require hospitalization depends on how commonly 
infants with cCMV require multiple hospitalizations in the first year of life. Our estimates of 
symptomatic cCMV-related hospitalizations among infants <1 month of age are 
underestimates as data on age in months was suppressed by some states and our 
extrapolations were based only on those hospitalizations with available data on age in 
months. Furthermore, our data did not allow us to determine if cCMV was the principal 
cause of hospitalization. Our inclusion of all hospitalizations with a code for cCMV may 
have overestimated symptomatic cCMV hospitalization rates by including some 
hospitalizations in which cCMV infection was present but did not contribute to the 
hospitalization. However, given that cCMV infection is not routinely screened for in the 
United States, this seems unlikely. Coding practices for cCMV-related hospitalizations have 
not been assessed and we may have missed symptomatic cCMV-related hospitalizations that 
were coded for using the CMV code (078.5), which does not specify congenital infection. 
Including the CMV code (078.5) in our case definition for symptomatic cCMV-related 
hospitalizations would have captured an additional 1576 hospitalizations among infants <1 
year, increasing the hospitalization rate by 30%, but would only have increased the 
hospitalization rate among infants <1 month by 14%. Data on treatments given during 
hospitalization were not available in the discharge records nor were laboratory testing 
results, which may have provided confirmation of a cCMV diagnosis. It is likely that a 
portion of the stay and costs among infants born <1500 g were not related to cCMV and we 
overestimated costs for this group; however, cCMV has been shown to cause low birth 
weight.14,17,18
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Our analysis illustrates the substantial disease and economic burden of symptomatic cCMV 
among infants <1 year of age in the United States with costs of hospitalizations estimated to 
range from at least $10 to $14.3 million annually. However, hospitalizations reflect only a 
part of the costs associated with symptomatic cCMV during the first year of life. cCMV has 
been identified as the leading infectious cause of neurodevelopmental disabilities and 
impairments, affecting similar numbers of children as Down syndrome.19 Further research is 
needed to better understand the full impact of the burden of disease of symptomatic cCMV 
during the first year of life and throughout the life span. Although hospital discharge data 
likely underestimates the true number of symptomatic cCMV-related hospitalizations, these 
data can be useful for tracking trends and providing estimates of the burden of severe, 
symptomatic cCMV infection and, in the future, monitoring impact of prevention strategies.
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Table 1
Estimated Numbers and Rates of cCMV-related Hospitalizations Not Associated With 
HIV and/ or Transplant-related Diagnoses in Infants <1 Year of Age in the United States 
by Patient and Hospital Characteristics, 1997–2009
Infants <1 Year
Patient Characteristics N (SE) Rate per 100,000 (95% CI) P Value
Total overall 3734 (125) 18.6 (18.5, 18.7)
 Annual average 747 (26)
Sex 0.001
 Male 2010 (82) 19.6 (19.5, 19.7)
 Female 1723 (76) 17.6 (17.5, 17.7)
Race/ethnicity* 0.001
 White (non-Hispanic) 1312 (76) 11.5 (11.4, 11.6)
 Black (non-Hispanic) 697 (54) 23.5 (23.3, 23.6)
 Hispanic 596 (53) 13.0 (12.8, 13.2)
 Asian/Pacific Islander 111 (17) 12.1 (11.7, 12.5)
 Other 203 (24) —
Region 0.72
 Northeast 582 (47) 17.3 (17.1, 17.4)
 Midwest 789 (71) 18.0 (17.8, 18.2)
 South 1575 (98) 21.2 (21.1, 21.3)
 West 788 (63) 16.0 (15.8, 16.2)
Year 0.69
 1997 763 (50) 20.3 (20.2, 20.4)
 2000 677 (58) 17.5 (17.3, 17.7)
 2003 700 (50) 17.3 (17.2, 17.4)
 2006 770 (50) 18.5 (18.4, 18.6)
 2009 823 (47) 19.3 (19.2, 19.4)
Hospital characteristics N (SE) Proportion (%)
Hospital type
 Urban teaching 2698 (117) 72.3
 Urban non-teaching 816 (40) 21.8
 Rural 109 (12) 2.9
Hospital size
 Small 472 (53) 12.6
 Medium 888 (64) 23.8
 Large 2263 (96) 60.6
Payment information
 Medicaid 2202 (89) 59.0
 Private/HMO 1214 (63) 32.5
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Infants <1 Year
Patient Characteristics N (SE) Rate per 100,000 (95% CI) P Value
 Self-pay 117 (17) 3.1
 Other 189 (28) 5.1
Estimates were calculated using the KID dataset from the Healthcare Cost and Utilization Project.
*
Information on race/ethnicity was missing for 21.2% of cCMV-related hospitalizations.
HMO indicates health maintenance organization.
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Table 2
Medical Conditions and Procedures Identified Among Infants <1 Year of Age With 
cCMV-related Hospitalizations Not Associated With HIV and/ or Transplant-related 
Diagnoses in the United States, 1997–2009
Congenital CMV-related Hospitalizations by Age Group
Infants <1 Month* Infants <1 Year
N = 2042 N = 3734
N (SE) % N (SE) %
cCMV-related conditions
 Thrombocytopenia 986 (45) 48.3 1495 (64) 40.0
 Petechiae 87 (13) 4.3 136 (16) 3.6
 Hepatomegaly 31 (7) 1.5 71 (11) 1.9
 Splenomegaly
—
†
—
† 30 (9) 0.8
 Microcephaly 149 (16) 7.3 384 (33) 10.3
 Seizure 114 (22) 5.6 314 (34) 8.4
 Other neurological symptoms 153 (18) 7.5 238 (24) 6.4
 Hearing loss 82 (14) 4.0 247 (28) 6.6
 Chorioretinitis 41 (10) 2.0 79 (14) 2.1
 Any cCMV-related symptom 1233 (52) 60.4 2202 (89) 59.0
Other conditions
 Low birth weight 1185 (52) 58.0 1723 (73) 46.2
 Jaundice 897 (46) 43.9 1287 (62) 34.5
 Respiratory distress 1075 (51) 52.6 1766 (74) 47.3
 Pneumonia 110 (18) 5.4 264 (28) 7.1
 Reflux 69 (14) 3.4 277 (31) 7.4
 Hydrocephalus 74 (13) 3.6 166 (21) 4.4
 Failure to thrive
—
†
—
† 90 (16) 2.4
 Died 88 (13) 4.3 157 (18) 4.2
Procedures
 Mechanical ventilation 743 (42) 36.4 1163 (57) 31.2
 Transfusions 471 (35) 23.1 761 (48) 20.4
 Feeding tubes 52 (12) 2.6 130 (18) 3.5
Estimates were calculated using the KID dataset from the Healthcare Cost and Utilization Project.
*
Limited to data from hospitalizations among children with data on age in months. Age in months data was suppressed by some states.
†
Estimated numbers with a relative SE >0.3 are considered less precise or unreliable measurements.
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